Eiger BioPharmaceuticals, Inc. filed a notice for the selection of Successful Bidder in the US Bankruptcy Court for the sale of its substantially all its assets on April 19, 2024. As a result of the auction conducted on April 17, 2024, Sentynl Therapeutics, Inc., has been selected as the winning bidder for the sale of debtor?s substantially all its assets.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.75 USD | +22.22% | +22.22% | -59.17% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-59.17% | 4.07M | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+50.18% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- EIGR Stock
- News Eiger BioPharmaceuticals, Inc.
- Selection of Successful Bidder Filed by Eiger BioPharmaceuticals, Inc.